Traffic Alert: Texas Medical Center road closures/water and sewer repairs. Please plan ahead and use alternate routes when possible. Learn more >
Rongfu Wang

Rongfu Wang, PhD

Adjunct Professor of Oncology, Academic Institute
Full Affiliate Member, Research Institute
Houston Methodist


Phone:
713.441.7359


Biography

Dr. Wang received his Ph.D. from the University of Georgia in 1992. After receiving his doctoral degree in Molecular Genetics, Dr. Wang expanded his field of expertise by training with Dr. James Mullins in the Department of Microbiology and Immunology at Stanford University School of Medicine. In 1994, Dr. Wang joined the Surgery Branch in the Center for Cancer Research at the National Cancer Institute (NCI) in Bethesda, Maryland where he worked with Branch Chief, Dr. Steve Rosenberg, who is a pioneer of cancer immunotherapy. In 1996, Dr. Wang was promoted to Senior Principal Investigator. During his tenure at the NCI, Dr. Wang made insightful discoveries on how immune cells recognize solid tumors through specific cancer antigens and published a landmark paper in Science on the development of a novel genetic approach to identify cancer antigens recognized by CD4+ T cells. In 2000, Dr. Wang was appointed Associate Professor at Baylor College of Medicine in the Center for Cell and Gene Therapy and the Department of Pathology and Immunology. He was promoted to full Professor in 2004. His lab studies novel mechanisms in tumor immunity and tolerance, innate immune regulation, regulatory T cell biology, inflammation, and epigenetics.

Throughout his career Dr. Wang has published over hundred papers in the top class of journals, including Science, Cell, Nature Biotechnology, Nature Immunology, Cell Metabolism and Immunity, and has over 20 patents. His work has been supported by many grants from NIH, DoD, American Cancer Society, Cancer Research Institute and CPRIT.

Description of Research

Research interests in Dr. Wang's laboratory include

  • cancer immunotherapy,
  • immune regulation in infectious and tumor immunity;
  • innate immune signaling and inflammation in diseases, 3) epigenetic reprogramming of cancer and immune cells. 

Areas Of Expertise

Cancer immunology Cancer immunotherapy Innate immune signaling Epigenetics of cancer and stem cells
Education & Training

Postdoctoral Fellowship, Surgery Branch, National Cancer Institute, Bethesda, MD
PhD, University of Georgia
Postdoctoral Fellowship, Stanford University
Publications

USP3 plays a critical role in the induction of innate immune tolerance
Duan, T, Feng, Y, Du, Y, Xing, C, Chu, J, Ou, J, Liu, X, Zhu, M, Qian, C, Yin, B, Wang, HY, Cui, J & Wang, RF 2023, , EMBO Reports, vol. 24, no. 12, e57828. https://doi.org/10.15252/embr.202357828

ZEB1 loss increases glioma stem cell tumorigenicity and resistance to chemoradiation
Hanna, GK, Madany, M, Tay, ASMS, Edwards, LA, Kim, S, Michael, JS, Nuno, M, Thomas, T, Li, A, Berel, D, Black, KL, Fan, X, Zhang, W, Rudnick, JD, Wang, R & Yu, JS 2023, , Journal of Neurosurgery, vol. 138, no. 5, pp. 1313-1324. https://doi.org/10.3171/2022.7.JNS22259

The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C, Liu, X, Chang, CY, Wang, HY & Wang, RF 2023, , Genes, vol. 14, no. 5, 1008. https://doi.org/10.3390/genes14051008

Correction: Stage-Dependent and Locus-Specific Role of Histone Demethylase Jumonji D3 (JMJD3) in the Embryonic Stages of Lung Development
Li, Q, Wang, HY, Chepelev, I, Zhu, Q, Wei, G, Zhao, K & Wang, RF 2023, , PLoS Genetics, vol. 19, no. 3, e1010701, pp. e1010701. https://doi.org/10.1371/journal.pgen.1010701

Function and regulation of cGAS-STING signaling in infectious diseases
Du, Y, Hu, Z, Luo, Y, Wang, HY, Yu, X & Wang, RF 2023, , Frontiers in immunology, vol. 14, 1130423. https://doi.org/10.3389/fimmu.2023.1130423

Activated T cell therapy targeting glioblastoma cancer stem cells
Miyaguchi, K, Wang, H, Black, KL, Shiao, SL, Wang, R & Yu, JS 2023, , Scientific Reports, vol. 13, no. 1, 196, pp. 196. https://doi.org/10.1038/s41598-022-27184-w

Corrigendum: PHF20 promotes glioblastoma cell malignancies through a WISP1/BGN-dependent pathway. PHF20 promotes glioblastoma cell malignancies through a WISP1/BGN-dependent pathway (Frontiers in Oncology, (2020), 10, (573318), 10.3389/fonc.2020.573318)
Ma, Q, Long, W, Xing, C, Jiang, C, Su, J, Wang, HY, Liu, Q & Wang, R 2023, , Frontiers in Oncology, vol. 13, 1157694, pp. 1157694. https://doi.org/10.3389/fonc.2023.1157694

Activation of cGAS-STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b+Ly6Chi Proinflammatory Monocytes
Du, Y, Luo, Y, Hu, Z, Lu, J, Liu, X, Xing, C, Wu, J, Duan, T, Chu, J, Wang, HY, Su, XZ, Yu, X & Wang, RF 2022, , Advanced Science, vol. 9, no. 22, 2103701, pp. e2103701. https://doi.org/10.1002/advs.202103701

Interaction between microbiota and immunity and its implication in colorectal cancer
Xing, C, Du, Y, Duan, T, Nim, K, Chu, J, Wang, HY & Wang, RF 2022, , Frontiers in immunology, vol. 13, 963819, pp. 963819. https://doi.org/10.3389/fimmu.2022.963819

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
Liu, X, Xu, Y, Xiong, W, Yin, B, Huang, Y, Chu, J, Xing, C, Qian, C, Du, Y, Duan, T, Wang, HY, Zhang, N, Yu, JS, An, Z & Wang, R 2022, , Journal for immunotherapy of cancer, vol. 10, no. 3, e004035. https://doi.org/10.1136/jitc-2021-004035

Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T, Du, Y, Xing, C, Wang, HY & Wang, RF 2022, , Frontiers in immunology, vol. 13, 812774, pp. 812774. https://doi.org/10.3389/fimmu.2022.812774

Erratum: Selection of reference genes for gene expression studies in human bladder cancer using SYBR-Green quantitative polymerase chain reaction (Oncol Lett (2017) 14 ( 6001-6011) DOI: 10.3892/ol.2017.7002)
Zhang, C, Wang, YQ, Jin, G, Wu, S, Cui, J & Wang, RF 2022, , Oncology Letters, vol. 23, no. 3, 85. https://doi.org/10.3892/ol.2022.13205

A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Hu, JL, Omofoye, OA, Rudnick, JD, Kim, S, Tighiouart, M, Phuphanich, S, Wang, H, Mazer, M, Ganaway, T, Chu, RM, Patil, CG, Black, KL, Shiao, SL, Wang, R & Yu, JS 2022, , Clinical Cancer Research, vol. 28, no. 4, pp. 689-696. https://doi.org/10.1158/1078-0432.CCR-21-2867

Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas
Hsu, R, Baca, Y, Xiu, J, Wang, R, Bodor, JN, Kim, C, Khan, H, Mamdani, H, Nagasaka, M, Puri, S, Liu, SV, Korn, WM & Nieva, JJ 2021, , Oncotarget, vol. 12, no. 25, pp. 2449-2458. https://doi.org/10.18632/ONCOTARGET.28132

Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice
Mojiri, A, Walther, BK, Jiang, C, Matrone, G, Holgate, R, Xu, Q, Morales, E, Wang, G, Gu, J, Wang, R & Cooke, JP 2021, , European heart journal, vol. 42, no. 42, pp. 4352-4369. https://doi.org/10.1093/eurheartj/ehab547

Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication
Chu, J, Xing, C, Du, Y, Duan, T, Liu, S, Zhang, P, Cheng, C, Henley, J, Liu, X, Qian, C, Yin, B, Wang, HY & Wang, RF 2021, , Nature Metabolism, vol. 3, no. 11, pp. 1466-1475. https://doi.org/10.1038/s42255-021-00479-4

Microbiota regulate innate immune signaling and protective immunity against cancer
Xing, C, Wang, M, Ajibade, AA, Tan, P, Fu, C, Chen, L, Zhu, M, Hao, ZZ, Chu, J, Yu, X, Yin, B, Zhu, J, Shen, WJ, Duan, T, Wang, HY & Wang, RF 2021, , Cell Host and Microbe, vol. 29, no. 6, pp. 959-974.e7. https://doi.org/10.1016/j.chom.2021.03.016

BECN2 (beclin 2) Negatively Regulates Inflammasome Sensors Through ATG9A-Dependent but ATG16L1- and LC3-Independent Non-Canonical Autophagy
Deng, G, Li, C, Chen, L, Xing, C, Fu, C, Qian, C, Liu, X, Wang, HY, Zhu, M & Wang, RF 2021, , Autophagy. https://doi.org/10.1080/15548627.2021.1934270

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway
Ma, Q, Long, W, Xing, C, Jiang, C, Su, J, Wang, HY, Liu, Q & Wang, RF 2020, , Frontiers in Oncology, vol. 10, 573318, pp. 573318. https://doi.org/10.3389/fonc.2020.573318

Beclin 2 negatively regulates innate immune signaling and tumor development
Zhu, M, Deng, G, Tan, P, Xing, C, Guan, C, Jiang, C, Zhang, Y, Ning, B, Li, C, Yin, B, Chen, K, Zhao, Y, Wang, HY, Levine, B, Nie, G & Wang, RF 2020, , Journal of Clinical Investigation, vol. 130, no. 10, pp. 5349-5369. https://doi.org/10.1172/JCI133283